Neuro Rx (Repurposed)

Low-dose lithium

Grade and summary pending review Evidence Grade Strength of published clinical evidence — not a safety rating or a recommendation. How to read this

Dimension Scores

Human Outcome

•

Biomarker Relevance

•

Signal Source Quality

•

Organ Specificity

•

Interaction Certainty

•

Translational Maturity

•

Per-dimension evidence strength is part of the full analysis Unlock full analysis

No indication-level signals recorded yet. The grade above has not been decomposed, so it should be read as a whole-compound assessment rather than a claim about any one indication.

Evidence Summary

One of the most scientifically intriguing dementia-prevention candidates — a 2025 mechanism plus three small trials all point the same direction. But the human evidence is still small and pilot-scale, and when the trials are pooled together the cognitive benefit is not yet statistically confirmed. Lithium also carries real kidney and thyroid risks and needs medical supervision. Important: prescription lithium carbonate at controlled low doses is NOT the same as over-the-counter 'trace lithium' or lithium orotate supplements, which have no comparable trial evidence.

Safety Considerations

Narrow therapeutic window — kidney and thyroid toxicity risk; requires medical monitoring of blood levels. Trials use deliberately subtherapeutic doses. Prescription lithium carbonate (studied) is distinct from OTC lithium orotate (not studied). Evidence is fast-moving — this grade is likely to change as larger trials report.

Evidence Signals (0)

🔒

Create a free account to see signal-level evidence grades.

Create a free account

Products Containing Low-dose lithium

No commercial products are currently listed for this molecule.

This evidence profile reflects publicly available research as of October 22, 2026. Evidence grades may change as new research is published. ClinEvident grades the quality of published evidence — it does not evaluate the efficacy of any specific commercial product.